eli lilly glp-1 agonist FDA just approved orforglipron (Foundayo), Lilly's oral receptor for obesity. In the ATTAIN-1 phase 3 trial (n=3,127), published in the New England Journal of Medicine, patients on the highest lilly glp 1 agonist Lilly's

diffusum treatment, experimental rats exhibited significantly increased expression of the epithelial marker E-cadherin and decreased expression of mesenchymal markers (vimentin and N-cadherin) in gastric tissues

This boosts their efficacy significantly

Maryke Louw 7 min read Best red light therapy settings for injury treatment and exercise recovery Red light therapy can be effective for treating many sports injuries and supporting post-exercise recovery

Besides, the nNOS isoform also plays a significant role in the pathophysiology of irritable bowel syndrome (IBS) and other gastrointestinal disorders, including IBD

Glutathione is a powerhouse